Noor Ul Ain Rehman
Tue, March 31, 2026 astatine 10:06 AM CDT 2 min read
Insmed Incorporated (NASDAQ:INSM) reported full-year 2025 full revenues of $606.4 million, including BRINSUPRI revenues of $172.7 cardinal for the twelvemonth and $144.6 cardinal successful Q4. ARIKAYCE delivered $119.2 cardinal successful Q4 and $433.8 cardinal for the afloat year, representing 19% yearly maturation and exceeding the precocious extremity of guidance. The operation of accelerating commercialized uptake and expanding marketplace accidental suggests that 2026 could people a pivotal inflection constituent successful gross visibility and operating leverage.
Insmed Incorporated (NASDAQ:INSM) was founded successful 1988. Headquartered successful Bridgewater, New Jersey, Insmed is simply a planetary biopharmaceutical steadfast focused connected processing and commercializing therapies for patients with uncommon and superior diseases, with cardinal assets including brensocatib and Treprostinil Palmitil Inhalation Powder.
While we admit the imaginable of INSM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·